CANCER METABOLISM BASED THERAPEUTICS MARKET ANALYSIS

Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types, which is expected to boost the growth of cancer metabolism-based therapeutics market

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths U.S. Moreover, according to Cancer Research UK, approximately 3,102 new cases were diagnosed with acute myeloid leukemia (AML) in U.K. during 2014-2016, and around 2,598 deaths occurred during 2015-2017. 

According to American Cancer Society reports published in 2019 nearly 1,762,450 new cancer cases will be diagnosed in the U.S An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

Moreover, increasing in strategic partnerships by major players operating in cancer metabolism based therapeutics market to increase their market presence and product offering is anticipated to propel the market growth during the forecast period.

For instance, on January 2019, Celgene entered into a partnership agreement with Kyn Therapeutics for development of novel immune-oncology therapies. According to the partnership agreement Kyn Therapeutics will be responsible for research and development activities for phase I-b and Celgene will lead the commercialization and development of Kyn’s aryl hydrocarbon receptor (AHR) antagonist program and kynurenine-degrading enzyme program.